Payment overview · 2025
General Payments
$215.75
11 reported records · 8 companies
Healthcare provider profile · identity verified
Gauri G. Kanhere, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RIO GRANDE CITY, TX · NPI 1710910773
Verified facts
What the public records show
CMS Open Payments records show Gauri G. Kanhere, M.D. received $215.75 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synjardy by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.62 | 24.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.65 | 22.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.91 | 12.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.32 | 9.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.78 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.20 | 8.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.18 | 8.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.09 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.75 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 279 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 255 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 77 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
77 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
279 | 76 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
255 | 71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 818 | 335 |
| Losartan Potassium | Losartan Potassium | 456 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 426 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 153 |
| Alprazolam | Alprazolam | 358 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 344 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 121 |
| Montelukast Sodium | Montelukast Sodium | 315 | 124 |
| Gabapentin | Gabapentin | 295 | 93 |
| Metformin Hcl | Metformin Hcl | 288 | 115 |
| Farxiga | Dapagliflozin Propanediol | 279 | 76 |
| Lisinopril | Lisinopril | 278 | 109 |
| Jardiance | Empagliflozin | 255 | 71 |
| Ozempic | Semaglutide | 255 | 54 |
| Omeprazole | Omeprazole | 240 | 90 |
| Sertraline Hcl | Sertraline Hcl | 229 | 79 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 72 |
| Alendronate Sodium | Alendronate Sodium | 172 | 66 |
| Memantine Hcl | Memantine Hcl | 170 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 67 |
| Carvedilol | Carvedilol | 143 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 53 |
| Pregabalin | Pregabalin | 140 | 26 |
| Famotidine | Famotidine | 136 | 45 |
| Meclizine Hcl | Meclizine Hcl | 131 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 41 |
| Furosemide | Furosemide | 123 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 115 | 41 |
| Xarelto | Rivaroxaban | 115 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 28 |
| Trulicity | Dulaglutide | 105 | 26 |
| Simvastatin | Simvastatin | 92 | 35 |
| Eliquis | Apixaban | 91 | 25 |
| Tramadol Hcl | Tramadol Hcl | 89 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 87 | 27 |
| Metformin Hcl Er | Metformin Hcl | 86 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 28 |
| Allopurinol | Allopurinol | 81 | 25 |
| Meloxicam | Meloxicam | 78 | 21 |
| Linzess | Linaclotide | 77 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 21 |
| Ezetimibe | Ezetimibe | 66 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 31 |
| Tradjenta | Linagliptin | 61 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 18 |
| Memantine Hcl Er | Memantine Hcl | 54 | 18 |
| Donepezil Hcl | Donepezil Hcl | 53 | 22 |
| Finasteride | Finasteride | 53 | 17 |
| Myrbetriq | Mirabegron | 52 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 15 |
| Entresto | Sacubitril/Valsartan | 49 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | 21 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Irbesartan | Irbesartan | 48 | suppressed |
| Nifedipine Er | Nifedipine | 48 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 20 |
| Baclofen | Baclofen | 45 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 17 |
| Enalapril Maleate | Enalapril Maleate | 41 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 15 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Dutasteride | Dutasteride | 35 | 12 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Valsartan | Valsartan | 35 | 13 |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 26 | suppressed |
| Glipizide | Glipizide | 26 | 13 |
| Prolia | Denosumab | 26 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 15 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lamotrigine Er | Lamotrigine | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 15 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | 12 |
| Azithromycin | Azithromycin | 20 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Clonidine | Clonidine | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | 11 |
| Topiramate | Topiramate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | 11 |
| Prednisone | Prednisone | 11 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.75 · 11 records | PFIZER INC. | ABRYSVO, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, LINZESS, NEXLETOL, PREVNAR 20, VRAYLAR, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error